ArticleScientific reports2025
Genomic and functional characterization of a novel temperate Coventryvirus phage infecting Staphylococcus pseudintermedius.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The rise of methicillin-resistant Staphylococcus pseudintermedius (MRSP), a multidrug-resistant zoonotic pathogen with strong biofilm-forming ability, highlights the urgent need for alternative therapies. Here, we report the isolation and comprehensive characterization of vB_SpsS_VL4 (VL4), a novel temperate phage obtained from sewage using a clinical MRSP isolate. VL4 genome (39,788 bp) contains 68 open reading frames (ORFs) with no virulence, resistance, or toxin genes and encodes lysis proteins with Cysteine, Histidine-dependent Amidohydrolase/Peptidase (CHAP) domains. Genomic and phylogenetic analyses classified VL4 as a new species within the Coventryvirus genus. Despite its temperate nature, VL4 demonstrated efficient replication (latent period 50 min; burst size 56 PFU per cell), remained viable at neutral pH and temperatures up to 37 °C, and significantly suppressed the host bacterial growth. Among 31 S. pseudintermedius clinical isolates, 27 (87%) strains were susceptible to VL4, while no activity was detected against Staphylococcus aureus. Moreover, VL4 inhibited biofilm formation and partially degraded mature MRSP biofilms. Collectively, these findings identify VL4 as a promising Coventryvirus phage with potential for future engineering and therapeutic development against difficult-to-treat MRSP infections.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.